Skip to main content

Table 2 Cardiovascular events among propensity score-matched MSU crystal exposed and unexposed individuals

From: Is urate crystal precipitation a predictor of cardiovascular risk in hyperuricemic patients? A Danish cohort study

 

MSU crystals

No MSU crystals

HR (95 % CI)

HR (95 % CI)

(events / person-year)

(events / person-year)

no stratification by urate level

stratified by urate level

APTC

46 / 1026

34 / 1009

1.33 (0.85–2.07)

0.86 (0.52–1.43)

Nonfatal MI

11 / 1026

9 / 1009

1.22 (0.50–2.94)

1.04 (0.37–2.90)

Nonfatal stroke

17 / 1026

11 / 1009

1.50 (0.70–3.20)

1.13 (0.49–2.61)

CV death

18 / 1026

14 / 1009

1.27 (0.63–2.56)

0.59 (0.26–1.32)

All-cause mortality

46 / 1026

40 / 1009

1.14 (0.75–1.74)

0.74 (0.45–1.21)

  1. APTC AntiPlatelet Trialists’ Collaboration, CI confidence interval, CV cardiovascular, HR Hazard ratio, MI myocardial infarction, MSU monosodium urate
  2. The no-crystal group was set as reference